source
- San Diego’s Seawolf Therapeutics raises $100M to develop non-viral gene therapies for obesity, muscle loss and osteoporosisSan Diego‑based Seawolf Therapeutics announced it has closed a $100 million financing round to fund its platform for non‑viral gene therapies. The company says its approach tackles a long‑standing…
- FDA approves Bayer’s Sunharbo, first Factor XIa inhibitor to lower stroke recurrence riskThe Food and Drug Administration has approved Bayer's new medication intended to prevent another stroke in patients who have already experienced one. The drug, sold under the brand name Sunharbo,…